Related references
Note: Only part of the references are listed.Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
R. Balena et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
Chun-jun Li et al.
CARDIOVASCULAR DIABETOLOGY (2012)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Y. Seino et al.
DIABETES OBESITY & METABOLISM (2012)
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
S. E. Inzucchi et al.
DIABETOLOGIA (2012)
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction
Marcus Lind et al.
PRIMARY CARE DIABETES (2012)
Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes A Randomized, Controlled Trial
John B. Buse et al.
ANNALS OF INTERNAL MEDICINE (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
Rena R. Wing et al.
DIABETES CARE (2011)
Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit
K. Y. Thong et al.
DIABETES OBESITY & METABOLISM (2011)
The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements
Wendy Lane et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Contribution of change in glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 diabetic patients
H. J. Jansen et al.
ENDOCRINE (2011)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
Exenatide therapy in insulin-treated type 2 diabetes and obesity
U. A. Nayak et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2010)
Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice Over Two Years in an Academic Endocrinology Outpatient Setting
Nancy M. Yoon et al.
CLINICAL THERAPEUTICS (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Appropriate Physical Activity Intervention Strategies for Weight Loss and Prevention of Weight Regain for Adults
Joseph E. Donnelly et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2009)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Glucagon-like peptide-1, glucose homeostasis and diabetes
Jens J. Holst et al.
TRENDS IN MOLECULAR MEDICINE (2008)
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients
A Sallé et al.
BRITISH JOURNAL OF NUTRITION (2005)
Timely initiation of basal insulin
MC Riddle
AMERICAN JOURNAL OF MEDICINE (2004)
Share Paper
